

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

Assignment ID: PATI907044

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
JANSSEN BIOTECH, INC.	02/04/2025
<b>RECEIVING PARTY DATA</b>	
<b>Company Name:</b>	JANSSEN PHARMACEUTICA NV
<b>Street Address:</b>	Turnhoutseweg 30
<b>City:</b>	Beerse
<b>State/Country:</b>	BELGIUM
<b>Postal Code:</b>	B-2340
<b>PROPERTY NUMBERS Total: 3</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16661671
<b>Application Number:</b>	17655519
<b>Patent Number:</b>	10478494
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(518452-5600
<b>Email:</b>	erica.hines@hrfmlaw.com,katie.todd@hrfmlaw.com
<b>Correspondent Name:</b>	Erica M. Hines
<b>Address Line 1:</b>	5 Columbia Circle
<b>Address Line 4:</b>	Albany, NEW YORK 12203
<b>ATTORNEY DOCKET NUMBER:</b>	3084.163A
<b>NAME OF SUBMITTER:</b>	Katherine Todd
<b>SIGNATURE:</b>	/Katherine Todd/
<b>DATE SIGNED:</b>	03/24/2025
<b>Total Attachments: 2</b>	
source=3084.163A - Executed Assignment - Janssen Biotech to Janssen Pharmaceutical#page1.tiff	
source=3084.163A - Executed Assignment - Janssen Biotech to Janssen Pharmaceutical#page2.tiff	

### Confirmatory General Assignment

WHEREAS, JANSSEN BIOTECH, INC., having its place of business at 800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 (hereinafter referred to as "Assignor") was the employer of one or more inventors of certain new and useful inventions ("Inventions") relating to

FGFR/PD-1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER

for which on April 3, 2015, United States Provisional Application No. 62/142,569 was filed at the United States Patent & Trademark Office;

and for which on March 24, 2016, United States Patent Application No. 15/079,136 was filed at the United States Patent & Trademark Office (now U.S. Patent No. 10,478,494);

WHEREAS, JANSSEN PHARMACEUTICA NV, having its place of business at Turnhoutseweg 30, Beerse, Belgium B-2340 (hereinafter referred to as "Assignee") acknowledges and confirms that it desired acquiring Assignor's entire right, title and interest or is desirous of acquiring Assignor's entire right, title and interest, if any (to the extent not already acquired), in the Inventions, including the right to claim priority thereof;

NOW, THEREFORE, BE IT KNOWN, that in view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor hereby acknowledges and confirms that it assigned and transferred or hereby assigns and transfers, for all countries in the world, to said Assignee its entire right, title and interest, including the right to claim priority, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof, including all substitutions, divisions, and continuations thereof, and in and to all Letters Patent, that may be granted for said inventions, and in and to all extensions, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.


And for purpose of obtaining patent protection in any foreign country, the Assignor hereby confirms its agreement that any right, title and interest, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof were, could be, and can be directly assigned by the inventors to the Assignee without explicit confirmation of the Assignor.

For avoidance of doubt, Assignor and Assignee agree that this Confirmatory General Assignment is being executed in an abundance of caution, and nothing herein constitutes an admission that any right, title and interest in the Inventions has not already been acquired by Assignee.

The Assignor agrees that this Confirmatory General Assignment is effective as of April 3, 2015.

IN TESTIMONY WHEREOF, the Assignor set hereunto its hand and seal this date.

FOR JANSSEN BIOTECH, INC.

  
Signature

Name

LIESBETH VERVOORT

Title of Authorized Signatory


AUTHORIZED SIGNATORY

Date

February 4, 2025

IN TESTIMONY WHEREOF, the Assignee set hereunto its hand and seal this date.

FOR JANSSEN PHARMACEUTICA NV

  
Signature

FILIP VERBERCKMOES

Name

Title of Authorized Signatory

Authorized signatory

Date

4 February 2025